## **Supplementary Materials**

## Development and clinical validation of a cross-sex translator of ECG drug responses

## Authors:

Roshni Shetty<sup>1</sup>, Stefano Morotti<sup>1</sup>, Vladimír Sobota<sup>2</sup>, Jason D. Bayer<sup>2</sup>, Haibo Ni<sup>1</sup>, Eleonora Grandi<sup>1</sup>\*

## Affiliations:

<sup>1</sup>Department of Pharmacology, University of California Davis; Davis, CA, USA.

<sup>2</sup>LIRYC Electrophysiology and Heart Modeling Institute, Fondation Bordeaux Université; Pessac-Bordeaux, France.

\*Corresponding author. Email: <u>ele.grandi@gmail.com</u>



**Fig. S1.** Drug plasma concentrations (bottom) vs time and corresponding QTc intervals (top; re-plotted from Fig. 3A) over time for males (pink) and females (blue) in clinical dataset 1 (27, 29). Solid lines represent the mean values, with shaded areas indicating the standard error of the mean (SEM), and each column corresponds to a separate drug administration and monitoring over a 24-hour period. All subjects received identical drug dosages prior to ECG monitoring during a particular drug evaluation (27).



**Fig. S2.** Drug plasma concentrations (bottom) vs time and corresponding QTc intervals (top; re-plotted from Fig. 4A) over time for males (pink) and females (blue) in clinical dataset 2 (29, 28); Solid lines represent the mean values, with shaded areas indicating the standard error of the mean (SEM), and each column corresponds to a separate drug administration and monitoring over a 24-hour period. All subjects received identical drug dosages prior to ECG monitoring during a particular drug combination evaluation and were dosed three times during the day (28).

**Table. S1. Effects of sex-diverging** plasma concentrations of quinidine on major ionic currents at maximum value of difference in mean plasma concentrations during quinidine administration in male vs female: 2065 ng/mL (2638 nM) in female vs 1425 ng/mL (1820 nM) in male at time point 2 hours (shown in **Fig. S1**). Row 1: IC50 (nM) and hill coefficient (n<sub>h</sub>) for ion channels blocked by quinidine (Data from (*34*)); Effect k =  $1/(1+([D]/IC50)^{nh})$ , where [D] is the drug concentration at 1820 nM (Row 2) and 263 8nM (Row 3).

Quinidine	I <sub>Kr</sub>	I <sub>NaL</sub>	I <sub>CaL</sub>	I <sub>Na</sub>	Ito	I <sub>K1</sub>	I <sub>Ks</sub>
CIPA							
IC50	992	9417	51592.3	12329	3487.4	39589919	4898.9
(n <sub>h</sub> )	(0.8)	(1.3)	(0.6)	(1.5)	(1.3)	(0.4)	(1.4)
k	0.3810	0.8944	0.8815	0.9463	0.6996	1	0.80
[D] = 1820 nM							
k	0.3138	0.8395	0.8562	0.9100	0.5898	0.9755	0.7041
[D] = 2638  nM							

**Table. S2.** Analysis of simulated QTc from baseline male and female cable models and following administration of quinidine concentration 1820 nM (Row 1) and 2638 nM (Row 2).

Quinidine	QTc	QTc simulated % increase	QTc simulated	QTc simulated %
Concentration	simulated	from baseline male	(female)	increase from baseline
[D]	(male)	(285.3ms)	ms	female
	ms			(340.8ms)
1820 nM	456.0	59.8%	533.4	56.5%
2638 nM	498.6	74.8%	582.0	70.8%